Join Omada Healths Chief Medical Officer, Carolyn Jasik, MD, and Clinical Pharmacist Ketan Patel, PharmD from Mercer as they share insights in how GLP-1 medications have expanded to treat additional chronic conditions, particularly CVD, and the questions that remain for how to integrate these treatments affordably and efficiently into care models
DIHEXA According to the Centers for Disease Control and Prevention, over 16 million people in the USA suffer from cognitive impairment of some sort
Overusing Albuterol increases the risk of adverse effects
These include semaglutide (Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), as well as liraglutide and dulaglutide
[19] Clinical trials are reporting weight loss of 20 to 40 lbs per year of use
doi: 10.1681/ASN.2018100971 35